AACE issues new Type 2 algorithm
The American Association of Clinical Endocrinology released an updated Type 2 diabetes algorithm that prioritizes GLP‑1RAs, GIP/GLP‑1 combinations, and SGLT2 inhibitors for efficacy, CV/renal benefit, weight loss and low hypoglycaemia risk — a change clinicians are widely sharing. (x.com)
AACE published the consensus statement “Algorithm for Management of Adults With Type 2 Diabetes — 2026 Update” in mid‑March 2026 as an Endocrine Practice consensus statement (published March 17, 2026). (read.qxmd.com) The update is organized into 11 discrete sections — including a newly added Diabetes Classification Algorithm, separate ASCVD‑risk pathways for dyslipidemia and hypertension, a comorbidities‑ and complications‑centric glycemic control pathway, a glucose‑centric pathway, insulin initiation/titration, and pharmacotherapy profiles for both T2D and obesity. (read.qxmd.com) Lead authorship and task‑force leadership are listed under Susan L. Samson, MD, PhD, FRCPC, FACE, with coauthors including Priyathama Vellanki, Lawrence Blonde, Irl B. Hirsch, Thanh D. Hoang and Scott D. Isaacs among others. (waltersport.com) The document explicitly expands the complications‑focused framework used in prior AACE work and calls out MASLD/MASH alongside heart failure, chronic kidney disease, ASCVD and OSA as conditions that should direct therapeutic choice within the algorithm. (docwirenews.com) Major clinician‑facing outlets and guideline aggregators published summaries the week of March 17–23, 2026 — coverage appeared on Endocrinology Advisor, Clinical Advisor, DocWire/ AACE “In the News,” and GuidelineCentral as the algorithm circulated through professional channels. (endocrinologyadvisor.com) The published consensus carries DOI 10.1016/j.eprac.2026.01.006 and AACE has noted the update will be incorporated into its clinical‑decision tools and companion summaries to aid point‑of‑care use. (guidelinecentral.com)
